Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice.

Tumor-specific immune tolerance limits the effectiveness of cancer vaccines. In addition, tumor vaccines alone have a limited potential for the treatment of measurable tumor burdens. This highlights the importance of identifying more potent cancer vaccine strategies for clinical testing. We tested immune-modulating doses of chemotherapy in combination with a granulocyte/macrophage-colony stimulating factor (GM-CSF)-secreting, HER-2/neu (neu)-expressing whole-cell vaccine as a means to treat existing mammary tumors in antigen-specific tolerized neu transgenic mice. Earlier studies have shown that neu transgenic mice exhibit immune tolerance to the neu-expressing tumors similar to what is observed in patients with cancer. We found that cyclophosphamide, paclitaxel, and doxorubicin, when given in a defined sequence with a GM-CSF-secreting, neu-expressing whole-cell vaccine, enhanced the vaccine's potential to delay tumor growth in neu transgenic mice. In addition, we showed that these drugs mediate their effects by enhancing the efficacy of the vaccine rather than via a direct cytolytic effect on cancer cells. Furthermore, paclitaxel and cyclophosphamide appear to amplify the T helper 1 neu-specific T-cell response. These findings suggest that the combined treatment with immune-modulating doses of chemotherapy and the GM-CSF-secreting neu vaccine can overcome immune tolerance and induce an antigen-specific antitumor immune response. These data provide the immunological rationale for testing immune-modulating doses of chemotherapy in combination with tumor vaccines in patients with cancer.

[1]  E. Jaffee,et al.  Cancer Vaccines , 1997, Current protocols in human genetics.

[2]  E. Jaffee,et al.  HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. , 2000, Cancer research.

[3]  T. Di Pucchio,et al.  Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. , 2000, Blood.

[4]  F. Marincola,et al.  Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. , 2000, Advances in immunology.

[5]  F. Marshall,et al.  Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. , 1999, Cancer research.

[6]  D. Mullins,et al.  Paclitaxel enhances macrophage IL-12 production in tumor-bearing hosts through nitric oxide. , 1999, Journal of immunology.

[7]  M. Sliwkowski,et al.  Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers , 1999, Oncogene.

[8]  S. Rosenberg,et al.  A new era for cancer immunotherapy based on the genes that encode cancer antigens. , 1999, Immunity.

[9]  C. Lowenstein,et al.  The Central Role of CD4+ T Cells in the Antitumor Immune Response , 1998, The Journal of experimental medicine.

[10]  D. Neuberg,et al.  Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[11]  L. Grochow,et al.  A Phase I Clinical Trial of Lethally Irradiated Allogeneic Pancreatic Tumor Cells Transfected with the GM-CSF Gene for the Treatment of Pancreatic Adenocarcinoma. The Johns Hopkins Oncology Center, Baltimore, Maryland , 1998 .

[12]  M. Mastrangelo,et al.  Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer , 1998, Cancer Immunology, Immunotherapy.

[13]  D Tripathy,et al.  Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. J. Ehrke,et al.  Thymic anti‐tumor effectors in mice cured of lymphoma by cyclophosphamide plus TNF‐α therapy: Phenotypic and functional characterization up to 20 months after initial tumor inoculation , 1998, International journal of cancer.

[15]  M. Imamura,et al.  Cyclophosphamide given after active specific immunization augments antitumor immunity by modulation of Th1 commitment of CD4+ T cells , 1998, Journal of surgical oncology.

[16]  M. Albert,et al.  Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs , 1998, Nature.

[17]  E. Proietti,et al.  Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice. , 1998, The Journal of clinical investigation.

[18]  S. Piantadosi,et al.  Immunomodulatory properties of antineoplastic drugs administered in conjunction with GM-CSF-secreting cancer cell vaccines. , 1998, International journal of oncology.

[19]  L. Grochow,et al.  A phase I clinical trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenocarcinoma. , 1998, Human gene therapy.

[20]  W. Hauck,et al.  Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  S. Goyert,et al.  CD14-dependent and CD14-independent signaling pathways in murine macrophages from normal and CD14 knockout mice stimulated with lipopolysaccharide or taxol. , 1997, Journal of immunology.

[22]  F. Marshall,et al.  Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. , 1997, Cancer research.

[23]  P. van der Bruggen,et al.  T cell defined tumor antigens. , 1997, Current opinion in immunology.

[24]  J. Miller,et al.  Mechanisms of tolerance to self. , 1996, Current opinion in immunology.

[25]  E. Jaffee,et al.  Enhanced immune priming with spatial distribution of paracrine cytokine vaccines. , 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[26]  A. Kruisbeek,et al.  Mechanisms underlying T-cell tolerance. , 1996, Current opinion in immunology.

[27]  K. Mettinger,et al.  The antitumoral effect of the immunomodulator AS101 and paclitaxel (Taxol) in a murine model of lung adenocarcinoma. , 1996, Journal of immunology.

[28]  E. Sotomayor,et al.  Tolerance and cancer: a critical issue in tumor immunology. , 1996, Critical reviews in oncogenesis.

[29]  D. Pardoll.  Paracrine cytokine adjuvants in cancer immunotherapy. , 1995, Annual review of immunology.

[30]  K. Sakaguchi,et al.  Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[31]  E. Jaffee,et al.  Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. , 1994, Science.

[32]  C. Manthey,et al.  Taxol provides a second signal for murine macrophage tumoricidal activity. , 1994, Journal of immunology.

[33]  M. J. Ehrke,et al.  Intracellular doxorubicin kinetics in lymphoma cells and lymphocytes infiltrating the tumor area in vivo: a flow cytometric study. , 1994, Oncology Research.

[34]  P. Matzinger.  Tolerance, danger, and the extended family. , 1994, Annual review of immunology.

[35]  Wei Chen,et al.  Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. , 1994, Cancer research.

[36]  P. Coulie,et al.  The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas , 1993, The Journal of experimental medicine.

[37]  P. Cristoforoni,et al.  Effect of new investigational drug taxol on oncolytic activity and stimulation of human lymphocytes , 1993, Gynecologic oncology.

[38]  A. Heintz,et al.  Dualistic effects of cis‐diammine‐dichloro‐platinum on the anti‐tumor efficacy of subsequently applied recombinant interleukin‐2 therapy: A tumor‐dependent phenomenon , 1993, International journal of cancer.

[39]  E. Jaffee,et al.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[40]  R. Schwartz.  Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy , 1992, Cell.

[41]  R. Steinman,et al.  Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor , 1992, The Journal of experimental medicine.

[42]  R. Cardiff,et al.  Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[43]  M. J. Ehrke,et al.  Adriamycin-induced modulation of host defenses in tumor-bearing mice. , 1992, Cancer research.

[44]  M. Croft,et al.  Helper T‐Cell Subsets: Phenotype, Function and the Role of Lymphokines in Regulating their Development , 1991, Immunological reviews.

[45]  M. J. Ehrke,et al.  Effects of anticancer drugs on the immune system in humans. , 1989, Seminars in oncology.

[46]  M. J. Ehrke,et al.  Alterations in murine host defense functions by adriamycin or liposome-encapsulated adriamycin. , 1988, Cancer research.

[47]  W. Enker,et al.  Inhibition of suppressor-cell activity by cyclophosphamide in patients with malignant melanoma. , 1987, Journal of biological response modifiers.

[48]  R. Germain.  Immunology: The ins and outs of antigen processing and presentations , 1986, Nature.

[49]  H. Maguire,et al.  Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. , 1986, Cancer research.

[50]  P. Greenberg,et al.  Treatment of disseminated leukemia with cyclophosphamide and immune cells: tumor immunity reflects long-term persistence of tumor-specific donor T cells. , 1984, Journal of immunology.

[51]  J. Turk,et al.  Effect of Cyclophosphamide on Immunological Control Mechanisms , 1982, Immunological reviews.

[52]  R. North.  Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells , 1982, The Journal of experimental medicine.

[53]  M. Mokyr,et al.  Importance of timing in cyclophosphamide therapy of MOPC-315 tumor-bearing mice. , 1980, Cancer research.

[54]  K. Nomoto,et al.  Immune response to syngeneic or autologous testicular cells in mice. I. Augmented delayed footpad reaction in cyclophosphamide-treated mice. , 1979, Clinical and experimental immunology.

[55]  Z. Pavelic,et al.  Increased primary cell-mediated immunity in culture subsequent to adriamycin or daunorubicin treatment of spleen donor mice. , 1977, Cancer research.

[56]  J. Turk,et al.  Reversal by cyclophosphamide of tolerance in contact sensitization. Tolerance induced by prior feeding with DNCB. , 1975, Immunology.

[57]  H. Maguire,et al.  Enhancement of dinitrochlorobenzene (DNCB) contact sensitization by cyclophosphamide in the guinea pig. , 1967, The Journal of investigative dermatology.